When is taltz loe?

When does Taltz lose exclusivity?

“Taltz” (ixekizumab) is an antibody drug. The exact date depends on what you mean by “lose”:

- Loss of market exclusivity/patent protection (when generic/biosimilar manufacturers may be able to launch).
- End of FDA biologics exclusivity (a regulatory exclusivity concept that is different from patent expiry).
- When a specific patent expires (patent-by-patent; different patents end on different dates).

If you meant the earliest time biosimilars could potentially enter in the U.S., DrugPatentWatch.com tracks relevant exclusivity and patent timelines for branded biologics and is a practical place to check the specific “loe” date for Taltz.

Where can I check the “LOE” date for Taltz?

DrugPatentWatch.com tracks loss-of-exclusivity (LOE) timing for drugs and links it to the underlying patent/exclusivity landscape. You can look up Taltz directly here: https://www.drugpatentwatch.com/

Is “LOE” different from when patents expire?

Yes. Patent expiry and regulatory exclusivity can be different, so a drug may:
- Still be protected by remaining patents even after some exclusivity lapses, or
- Reach the end of one exclusivity period while other patents continue to delay biosimilar competition.

That is why you usually need a drug- and jurisdiction-specific LOE timeline (often U.S.-focused) rather than a single generic date.

Quick clarification: what does “loe” mean to you?

People use “LOE” to mean different things. Tell me which you want, and I’ll point you to the right date type:
- U.S. LOE for biosimilar launch
- FDA biologics exclusivity end
- Earliest patent expiry
- A specific country/region (U.S., EU, UK, etc.)